195940.KQ HK Inno.N Corp.

Healthcare Pharmaceuticals KOSDAQ
34,250 KRW
Close of Oct 31, 2026
32,600 58,148
Market cap
KRW 970B
P/E
23.7x
P/B
0.72x
ROE
5.9%
Dividend yield
1.02%
Fundamental score
2.9/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 195940.KQ undervalued?

Graham number
Price34,250
Graham value39,407
Discount13.1%

195940.KQ trades 13.1% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

HK Inno.N Corp. fundamental analysis

14 of 22 checks passed

ROE 0/2

Low return on equity (5.9%), below 10%.

ROA 1/1

Return on assets (3.9%) is above the industry median (3.4%).

Profit Consistency 2/2

Profitable for 7 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (22.9%) is above the 5-year average (22.6% a year).

Earnings Growth vs Industry 1/1

Last year's EPS growth (22.9%) is above the industry median (6.6%).

Revenue Growth 1/2

Revenue grew 7.9% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (11.0%), 40% or less.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

No interest expense reported.

PE vs Market 0/1

PE (23.7x) is above the market median (11.3x).

PE vs Industry 0/1

PE (23.7x) is above the industry median (19.4x).

PBV 1/1

Price to book (0.7x) is below the industry median (0.8x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 17.0, limit 22.5).

PEG 0/1

PEG on 5-year earnings growth is 1.05, above 1.

Dividend Yield 0/2

Dividend yield (1.0%) is in the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 1/1

Payout ratio is 13.1%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

HK Inno.N Corp. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About HK Inno.N Corp.

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with …

Full company profile